Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
  • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
  • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D231/38—Nitrogen atoms
  • C07D231/40—Acylated on said nitrogen atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders

Definitions

• the invention relates to an improved process for the preparation of a polymorph of l-[tert-butyl- l-p-tolyl-lH-pyrazol-5-yl]-3-[4-(2-morpolinin-4-yl-ethoxy)naphthalen-l-yl]-urea (l) by crystallization from an alcohol.
• the invention relates to an improved process for the preparation of a polymorph of l-[tert-butyl-l-p-tolyl-lH-pyrazol-5-yl]-3-[4-(2-morpolinin-4-yl-ethoxy)naphthalen-l-yl]-urea (1) by crystallization from an alcohol, wherein the improvement is that crude (1) is treated with ethanol.
• Another aspect of the invention is the essentially pure polymorph of l-[tert-butyl-l-p-tolyl-lH- pyrazol-5-yl]-3-[4-(2-mo ⁇ polinin-4-yl-ethoxy)naphthalen-l-yl]-urea (1) which is obtainable by crystallization of the crude (1) with ethanol.
• the invention relates to a pharmaceutical composition
• a pharmaceutical composition comprising an effective amount of the essentially pure polymorph Form 1 of (1) in combination with at least one pharmaceutical excipient and to a method of treating an inflammatory disease which comprises administering to a patient in need of such treatment a therapeutically effective amount of an essentially pure polymorph of (1).
• Form 1 which is not contaminated by said by-products and other polymorphs is more compact and much less electrostatic than the contaminated Form 1 and may hence be more readily subjected to any treatment under the usual conditions of pharmaceutical technology and, in particular, of formulation on an industrial scale.
• the term "essentially pure” as used hereinbefore and hereinbelow relates to the polymorph Form 1, which is essentially free of other polymo ⁇ hic forms and by-products. As a rule it consists of at least 98 %, preferably of 98.5 to 100 , in particular of 99.85 to 99.99 % of said Form 1.
• the term as used hereinabove and hereinbelow encompasses any procedural step, in which crude (1) is brought in to contact with ethanol, preferably adding ethanol to (1) at ambient or elevated temperature, dissolving crude (1) in ethanol, optionally in the presence of a polar aprotic co-solvent such as for example DMSO, crystallizing (1) from a solution of (1) in ethanol by seeding with crystals of (1), by lowering the temperature and/or by dilution with water.
• the term includes washing of solid product (1) with ethanol, optionally followed by subsequent washing with water.
• crude (1) is first re-crystallized from ethanol and the solid product obtained by re-crystallization is subsequently washed with ethanol and water.
• the crude (1) is treated with ethanol at a temperature from 0 °C to 80 °C, in particular fromlO to 60 °C, most preferably from 25 to 50 °C.
• a mixture of 1 part per weight of crude (1) obtained according to the method described in example 1 of WO 01/04115, DMSO (0.5 to 2.5, in particular 1.5 part per weight) and ethanol (0.1 to 2.0, in particular 1.0 part per weight) is stirred at 0 °C to 45 °C, in particular at ambient temperature for 1 to 60, in particular 35 min..
• Charcoal (0.01 to 0.5, in particular 0.1 part per weight) is added to the resulting solution.
• the suspension is filtered and the residue washed with ethanol (1 to 5, in particular 3 part per weight). Seeding crystals are added to the resulting solution; subsequently water (2 to 10, in particular 4 part per weight) is added at 0 °C to 45 °C, in particular at 20-30 °C.
• the resulting suspension is cooled to ambient temperature and the solid product is isolated and washed with ethanol and water.
• the resulting crystals are dried at elevated temperature in particular at 40 to 70 °C to yield white crystals of polymo ⁇ h Form 1 of (1) with a purity of > 99.5 %
• 1,01-1,1 equivalents of 4-amino — 1-(2- mo ⁇ holinoethoxy)naphthalene (2) are reacted with 1 equivalent of 5-(2,2,2- trichloroethoxycarbonyl)amino-3-tert-butyl-l -p-tolylpyrazole (3) in the presence of 1 equivalent of a tertiary amine and a solvent consisting of DMSO, preferably 0.5 to 1.5, in particular about 0.8 to 1.1 parts per weight of DMSO with respect to (2) and ethyl acetate, preferably 1.0 to 10.0, in particular about 6.0 to8.0 parts per weight of ethyl acetate with respect to (2); isolation of crude (1); washing crude (1) with ethyl acetate; and treating the residue with ethanol.
• Preferred tertiary amines for example are triethylamine, diisopropylethylamine, N- methylpyrrolidine, DBU(l,8-diazabicyclo[5.4.0]undec-7-ene), DMAP(4- dimethylaminopyridine), N-methylmo ⁇ holine, pyridine or methyl pyridine.
• Most preferred tertiary amines are diisopropylethylamine or N-methylpyrrolidine.
• the reaction occurs at a temperature of about 0 - 100°C, preferably 5 - 15 °C, for about 0.5 - 24 hrs, preferably 3-4 hrs.
• a solution consisting essentially of 5-(2,2,2- trichloroethoxycarbonyl)amino-3-t-butyl-l -p-tolylpyrazole (3) (1 equivalent), 4-amino- 1 -(2- mo ⁇ holinethoxy)naphthalene (2) (free base, 1.02-1.08 equivalents), diisopropylethylamine (1 equivalent), DMSO (0.5 to 1.5 parts per weight with respect to (2)) and ethyl acetate (1.0 to 10.0 parts per weight with respect to (2)) is stirred at 60-100 °C. The mixture was allowed to cool to ambient temperature and stirred for 16 hrs at ambient temperature. Charcoal is added to the resulting solution.
• the resulting suspension is filtered and the residue washed with ethyl acetate.
• the organic layer is concentrated in vacuo.
• the residue is treated with ethanol and seeding crystals and subsequently water are added.
• the resulting solid product is isolated and washed with ethanol and water.
• the resulting crystals are dried at to yield white crystals of polymo ⁇ h Form 1 of (1) with a purity of at least 99.5 %.
• XRPD X-ray powder diffractogramm
• the process according to the invention allows to manufacture the pure polymo ⁇ h of (1) in higher purity and yields. Moreover, the process according to the invention for the preparation of (1) from (2) and (3) can be carried out with lower amounts of solvents than suggested by WO 01/04115, which is important for production in industrial scale with respect to environmental requirements and solvent management.
• the essentially pure polymo ⁇ h of the invention is useful for the treatment of inflammatory conditions. These encompass chronic inflammatory diseases including, but not limited to, osteoarthritis, multiple sclerosis, Guillain-Barre syndrome, Crohn's disease, ulcerative colitis, psoriasis, graft versus host disease, systemic lupus erythematosus and insulin-dependent diabetes mellitus.
• the essentially pure polymo ⁇ h of the invention can also be used to treat other disorders associated with the activity of elevated levels of proinflammatory cytokines such as responses to various infectious agents and a number of diseases of autoimmunity such as rheumatoid arthritis, toxic shock syndrome, diabetes and inflammatory bowel diseases.
• the essentially pure polymo ⁇ h of the invention being an inhibitor of cytokine production are expected to block inducible cyclooxygenase (COX-2) expression.
• COX-2 expression has been shown to be increased by cytokines and it is believed to be the isoform of cyclooxygenase responsible for inflammation (M.K. O'Banion et al, Proc. Natl. Acad. Sci. U.S.A, 1992, 89, 4888.)
• the essentially pure polymo ⁇ h would be expected to exhibit efficacy against those disorders currently treated with COX inhibitors such as the familiar NSAIDs. These disorders include acute and chronic pain as well as symptoms of inflammation and cardiovascular disease.
• the essentially pure polymo ⁇ h of the invention may be useful in the treatment of diseases mediated predominantly by neutrophils such as stroke and myocardial infarction, alone or following thrombolytic therapy, thermal injury, adult respiratory distress syndrome (ARDS), multiple organ injury secondary to trauma, acute glomerulonephritis, dermatoses with acute inflammatory components, acute purulent meningitis or other central nervous system disorders, hemodialysis, leukopherisis, granulocyte transfusion associated syndromes, and necrotizing entrerocolitis.
• neutrophils such as stroke and myocardial infarction, alone or following thrombolytic therapy, thermal injury, adult respiratory distress syndrome (ARDS), multiple organ injury secondary to trauma, acute glomerulonephritis, dermatoses with acute inflammatory components, acute purulent meningitis or other central nervous system disorders, hemodialysis, leukopherisis, granulocyte transfusion associated syndromes, and necrotizing entrerocolitis.
• the essentially pure polymo ⁇ h of the invention may be administered in any conventional dosage form in any conventional manner.
• Routes of administration include, but are not limited to, intravenously, intramuscularly, subcutaneously, intrasynovially, by infusion, sublingually, transdermally, orally, topically or by inhalation.
• the preferred modes of administration are oral and intravenous.
• the essentially pure polymo ⁇ h of this invention may be administered alone or in combination with adjuvants that enhance stability of the inhibitors, facilitate administration of pharmaceutic compositions containing them in certain embodiments, provide increased dissolution or dispersion, increase inhibitory activity, provide adjunct therapy, and the like, including other active ingredients.
• combination therapies utilize lower dosages of the conventional therapeutics, thus avoiding possible toxicity and adverse side effects incurred when those agents are used as monotherapies.
• the essentially pure polymo ⁇ h of the invention may be physically combined with the conventional therapeutics or other adjuvants into a single pharmaceutical composition.
• the essentially pure polymo ⁇ h may then be administered together in a single dosage form.
• the pharmaceutical compositions comprising such combinations of compounds contain at least about 5%, but more preferably at least about 20%, of an essentially pure polymo ⁇ h (w/w) or a combination thereof.
• the optimum percentage (w/w) of an essentially pure polymo ⁇ h may vary and is within the purview of those skilled in the art.
• the essentially pure polymo ⁇ h may be administered separately (either serially or in parallel). Separate dosing allows for greater flexibility in the dosing regime.
• dosage forms of the essentially pure polymo ⁇ h of this invention include pharmaceutically acceptable carriers and adjuvants known to those of ordinary skill in the art.
• carriers and adjuvants include, for example, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, buffer substances, water, salts or electrolytes and cellulose-based substances.
• Preferred dosage forms include, tablet, capsule, caplet, liquid, solution, suspension, emulsion, lozenges, syrup, reconstitutable powder, granule, suppository and transdermal patch. Methods for preparing such dosage forms are known (see, for example, H.C. Ansel and N.G.
• Dosage levels and requirements are well-recognized in the art and may be selected by those of ordinary skill in the art from available methods and techniques suitable for a particular patient. In some embodiments, dosage levels range from about 10-1000 mg/dose for a 70 kg patient. Although one dose per day may be sufficient, up to 5 doses per day may be given. For oral doses, up to 2000 mg/day may be required. As the skilled artisan will appreciate, lower or higher doses may be required depending on particular factors. For instance, specific dosage and treatment regimens will depend on factors such as the patient's general health profile, the severity and course of the patient's disorder or disposition thereto, and the judgment of the treating physician.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Immunology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (1)

Family

ID=32682346

Family Applications (1)

Country Status (6)

Cited By (14)

Citations (3)

Family Cites Families (1)

• 2003
  • 2003-12-03 US US10/727,214 patent/US20040138216A1/en not_active Abandoned
  • 2003-12-12 EP EP03795888A patent/EP1581502A1/en not_active Withdrawn
  • 2003-12-12 CA CA002511325A patent/CA2511325A1/en not_active Abandoned
  • 2003-12-12 WO PCT/EP2003/014128 patent/WO2004056783A1/en not_active Ceased
  • 2003-12-12 AU AU2003298178A patent/AU2003298178A1/en not_active Abandoned
  • 2003-12-12 JP JP2004561284A patent/JP2006513185A/ja active Pending

Patent Citations (3)

Also Published As

Similar Documents

Legal Events